Nvidia CEO Jensen Huang unveils new processors as company looks to strengthen its dominance in AI chip market (Eric Risberg, Associated Press)
Nvidia (NVDA)
Nvidia has unveiled its latest artificial intelligence (AI) chip, which it says is up to 30 times faster than its predecessor.
The new chip, named Blackwell B200, combines two chips of the same size into one chip as Nvidia's previous products.
“Blackwell GPUs are the powerhouse driving this new industrial revolution,” said NVIDIA CEO Jensen Huang at the company's annual GTC event in San Jose, attended by thousands of developers.
Read more: FTSE 100 LIVE: European markets cautious as central banks patrol interest rates
“Generative AI is the defining technology of our time. By working with the world's most dynamic companies, we will realize the potential of AI across every industry,” Huang added in the press release. .
Nvidia has an 80% share of the data center AI chip market and hopes to solidify its dominance with this latest chip.
The company is the third most valuable company in the United States, behind Microsoft (MSFT) and Apple.
Apple is in talks to potentially integrate Google's (GOOG) artificial intelligence platform Gemini into the iPhone, Bloomberg reports.
Apple is in “active negotiations” to license Gemini's AI model in order to integrate its generative AI capabilities into iPhone software updates scheduled for later this year.
Apple's model is likely to power on-device generation AI with iOS 18 released later this year, while cloud-based AI capabilities such as text and image generation will be offered through partnerships with Google and others. There is a possibility that
“Consuming that Apple has an installed base of 2.2 billion iOS devices, usage-based licensing agreements can be very costly for Apple, while fixed licenses for cloud-based usage are costly for partners. It’s not economical,” Bank of America analyst Wamsi Mohan said.
“It seems most likely that there will be a fixed fee on a device-by-device basis, but functionality will be more limited. Apple will continue to develop its technology in-house while increasing its time-to-market.” We could also use this as a shortening approach,” he added.
story continues
Unilever has warned that up to 7,500 jobs are at risk as the Magnum maker outlines plans to spin off its ice cream division as a separate business.
The review is primarily aimed at saving around €800m (£684m) over the next three years. The plan would separate the ice cream business and split Unilever's remaining divisions into four divisions: Beauty & Wellbeing, Personal Care, Home Care and Nutrition.
The FTSE 100 consumer goods giant said it was accelerating its “growth action plan” to make it a “simpler, more focused company”.
“What shareholders expected from the new team at the top was action, and that's what happened today,” said Matt Blitzman, equity analyst at Hargreaves Lansdown.
“Ice cream has always seemed like a novelty compared to other product lines and has been underperforming recently.
Read more: If unregulated, AI could cause 'total extinction of humanity'
“While this move is not a huge shock, it is something that previous management teams have not been able to accomplish.
“We expect the market to react positively to this news, perhaps more due to decisive action than anything else, as Unilever is not a very expensive name at the moment.”
The organization said it plans to consult with affected staff about reducing staff, but did not specify where they would be placed.
AstraZeneca (AZN.L)
AstraZeneca has acquired oncology biotechnology company Fusion Pharmaceuticals for $2.4 billion as part of a plan to accelerate the development of next-generation cancer treatments.
Fusion, a Canadian biotechnology company whose shares trade in New York, is involved in radiopharmaceuticals, a rapidly growing field of cancer treatments that target specific organs, tissues and cells in the human body.
AstraZeneca said: “This acquisition delivers on AstraZeneca's ambition to transform cancer treatment and patient outcomes by replacing traditional treatments such as chemotherapy and radiotherapy with more targeted treatments. This will be a major step forward.”
The transaction includes an upfront cash transaction of $2.0 billion, with a total transaction value of $2.4 billion, subject to additional contingent payments. The move follows AstraZeneca's $1 billion acquisition of French rare disease startup Amorite last week.
Video: Nvidia CEO unveils latest powerful chips at 'AI Woodstock'
Download the Yahoo Finance app, available on Apple and Android.
